Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
FEMY vs KMTS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
KMTS Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 6–2 Matrix Metrics)
KMTS Overall Winner
6-Pillar Tally: FEMY 2 – 2 KMTS (2 Tie)
Matrix Metrics: FEMY 2 – 6 KMTS
As of Nov 16, 2026, Kestra Medical Technologies, Ltd. (KMTS) is the stronger overall head-to-head candidate over Femasys Inc. (FEMY) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). FEMY carries a Unified Composite Score of 52.6/100 (HOLD) at $1.28 (N/M Forward P/E, -763.9% operating margin), whereas KMTS carries 43.8/100 (HOLD) at $27.97 (N/M Forward P/E, -134.5% operating margin).
- Composite vs. Pillar Nuance: While FEMY currently prints a higher short-term Unified Composite Score (52.6/100 HOLD vs. KMTS 43.8/100 HOLD), KMTS captures the overall institutional head-to-head verdict (6–2 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (-134.5% vs. -763.9% operating margin) and revenue trajectory (+59.9% vs. -18.9% YoY).
- Technical & Structure Timing Caution: FEMY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.6); meanwhile KMTS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About FEMY vs KMTS
FEMY
Femasys Inc. Common Stock
$1.28
-9.86% 1D
Market Cap
$11.9M
TTM Revenue
$2.3M
Forward P/E
N/M
Beta / 30D Vol
4.01β · 72% Vol
Unified Composite Score
52.6
HOLD
Tech 61.0
Fund 62.0
Flow 50.0
Mom 64.0
Weinstein Technical Phase
Markdown · Sell / avoid
KMTS
Head-to-Head Winner
Kestra Medical Technologies, Ltd. Common Stock
$27.97
-2.34% 1D
Market Cap
$1.7B
TTM Revenue
$107M
Forward P/E
N/M
Beta / 30D Vol
1.84β · 63% Vol
Unified Composite Score
43.8
HOLD
Tech 21.0
Fund 39.0
Flow 50.0
Mom 40.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (FEMY 2 – 2 KMTS)
1. Valuation Multiples
FEMY
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
4.9x
15.5x
2. Growth & Scale
KMTS
Revenue Growth (YoY)
-18.9%
+59.9%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$2.3M
$107M
Market Cap
$11.9M
$1.7B
3. Profitability & Quality
KMTS
Gross Margin
60.9%
53.9%
Operating Margin
-763.9%
-134.5%
Net Profit Margin
0.0%
-140.4%
Return on Equity (ROE)
-425.0%
-73.7%
4. Balance Sheet & Cash Flow
FEMY
Cash Generation (TTM)
-$19M
-$117M
Cash Flow Margin
N/A
-109.7%
Net Cash / Leverage
-$658,045 Net Debt (0.65x D/E)
$53M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
Tie
Options Structure Phase
UNCLASSIFIED
UNCLASSIFIED
Current IV / %ile
N/A (N/A)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Neutral
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Instruments & Supplies Operator
Medical Instruments & Supplies Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: FEMY (2) vs KMTS (6)| Institutional Metric | FEMY | KMTS | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $11.9M | $1.7B | KMTS | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | -18.9% | +59.9% | KMTS | |
| Operating Margin (TTM) | -763.9% | -134.5% | KMTS | |
| Net Profit Margin | 0.0% | -140.4% | FEMY | |
| Return on Equity (ROE) | -425.0% | -73.7% | KMTS | |
| 52-Week Range Position | 17% ($0–$6) | 73% ($17–$32) | KMTS | |
| Beta / 30D Volatility | 4.01β · 72% Vol | 1.84β · 63% Vol | KMTS | |
| Unified Institutional Score | 52.6 / 100 (HOLD) | 43.8 / 100 (HOLD) | FEMY | |
| Trailing 12M Revenue (USD) | $2.3M | $107M | Scale | |
| Gross Profit Margin (TTM) | 60.9% | 53.9% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 4.9x EV/Rev | N/M PEG · 15.5x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$19M (-$658,045 Net Debt (0.65x D/E)) | -$117M ($53M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
KMTS +25.1 pp
3M Horizon
KMTS +41.96 pp
6M Horizon
FEMY +210.03 pp
1Y Horizon
FEMY +42.5 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | FEMY Revenue | KMTS Revenue | FEMY Op. Margin | KMTS Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2020 | $0M | N/A | -668.0% | N/A | FEMY |
| FY2021 | $0M | N/A | -706.7% | N/A | FEMY |
| FY2022 | $0M | N/A | -961.7% | N/A | FEMY |
| FY2023 | $0M | N/A | -1353.4% | N/A | FEMY |
| FY2024 | $0M | $30M | -1091.8% | -305.8% | KMTS |
| FY2025 | $0M | $60M | -767.0% | -177.8% | KMTS |
| FY2026 | N/A | $100M | N/A | -141.6% | KMTS |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
FEMY
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact FEMY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
KMTS
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact KMTS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
FEMY Moat Profile
Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
KMTS Moat Profile
Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ FEMY vs KMTS Key Questions & Quantitative Answers
As of Nov 16, 2026, Kestra Medical Technologies, Ltd. (KMTS) is the stronger overall head-to-head candidate over Femasys Inc. (FEMY) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). FEMY carries a Unified Composite Score of 52.6/100 (HOLD) at $1.28 (N/M Forward P/E, -763.9% operating margin), whereas KMTS carries 43.8/100 (HOLD) at $27.97 (N/M Forward P/E, -134.5% operating margin). Composite vs. Pillar Nuance: While FEMY currently prints a higher short-term Unified Composite Score (52.6/100 HOLD vs. KMTS 43.8/100 HOLD), KMTS captures the overall institutional head-to-head verdict (6–2 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (-134.5% vs. -763.9% operating margin) and revenue trajectory (+59.9% vs. -18.9% YoY). Technical & Structure Timing Caution: FEMY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.6); meanwhile KMTS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
KMTS leads the Growth & Scale pillar: FEMY posts -18.9% YoY revenue growth and +0.0% YoY earnings growth on $2.3M TTM revenue (60.9% gross margin, -763.9% operating margin), compared with KMTS at +59.9% YoY revenue growth and +0.0% YoY earnings growth on $107M TTM revenue (53.9% gross margin, -134.5% operating margin). Across the 7-period historical trajectory (FY2020 to FY2026), FEMY cumulative revenue shifted N/A while KMTS shifted +233.3%. In operating R&D and SG&A reinvestment, FEMY deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for KMTS.
FEMY screens cheaper on headline valuation multiples. FEMY trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 4.9x EV/Revenue (unreported FCF margin), whereas KMTS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 15.5x EV/Revenue (-109.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FEMY (-425.0% ROE) versus KMTS (-73.7% ROE) capital efficiency.
In options market volatility and institutional positioning, FEMY carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.01β · 72% Vol realized risk). By comparison, KMTS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.84β · 63% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
KMTS vs FEMY · Reverse Pair
KMTS vs BBNX
· Sector Peer
KMTS vs CBLL
· Sector Peer
KMTS vs HTFL
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking